Literature DB >> 3159544

Return to ovulation following the use of long-acting injectable contraceptives: a comparative study.

J Garza-Flores, S Cardenas, V Rodríguez, M C Cravioto, V Diaz-Sanchez, G Perez-Palacios.   

Abstract

A comparative study was undertaken in twenty-four Mexican women who discontinued the use of depo-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) to assess the time required for the return to menses and ovulation. All subjects were exposed to long-acting injectable contraceptives for at least one year, and were followed prospectively. Serum progesterone levels were determined weekly in all subjects beginning 3 months after the last progestogen injection. Mean time to return to ovulation occurred significantly earlier (p less than 0.001) after NET-EN (2.6 months) as compared with DMPA (5.5 months). No correlation between the return to ovarian function and the duration of steroid exposure was found. The overall data was interpreted as demonstrating a clear-cut difference between the two long-acting progestogens in terms of ovulation suppression.

Entities:  

Keywords:  Age Factors; Americas; Anthropometry; Biology; Central America; Comparative Studies; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Methods--administraction and dosage; Corpus Luteum Hormones; Developed Countries; Developing Countries; Endocrine System; Examinations And Diagnoses; Family Planning; Gonadotropins; Gonadotropins, Pituitary; Hormones; Injectables--administraction and dosage; Laboratory Examinations And Diagnoses; Laboratory Procedures; Latin America; Medroxyprogesterone Acetate--administraction and dosage; Mexico; Norethindrone Enanthate--administraction and dosage; Norethindrone--administraction and dosage; North America; Ovulation Detection; Physiology; Population Characteristics; Progestational Hormones; Progesterone--analysis; Prolactin; Reproduction; Reproductive Control Agents; Research Methodology; Reversibility; Studies

Mesh:

Substances:

Year:  1985        PMID: 3159544     DOI: 10.1016/0010-7824(85)90004-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.

Authors:  Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo
Journal:  Lancet HIV       Date:  2015-07       Impact factor: 12.767

2.  Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.

Authors:  Renee Heffron; Sharon L Achilles; Laneta J Dorflinger; Janet P Hapgood; James Kiarie; Chelsea B Polis; Petrus S Steyn
Journal:  Contraception       Date:  2018-12-18       Impact factor: 3.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.